Cargando…
Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
INTRODUCTION: The clinical efficacy of osimertinib for patients with lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations is unclear. Few case reports exist on the successful treatment of such tumors with osimertinib. We report a case wherein osimertinib...
Autores principales: | Inagaki, Yuji, Tamiya, Akihiro, Matsuda, Yoshinobu, Azuma, Kouji, Adachi, Yuichi, Enomoto, Takatoshi, Kouno, Shunichi, Taniguchi, Yoshihiko, Saijo, Nobuhiko, Okishio, Kyoichi, Atagi, Shinji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572000/ https://www.ncbi.nlm.nih.gov/pubmed/33080698 http://dx.doi.org/10.1097/MD.0000000000022628 |
Ejemplares similares
-
Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status
por: Adachi, Yuichi, et al.
Publicado: (2019) -
Retrospective analysis of long‐term survival factors in patients with advanced non‐small cell lung cancer treated with nivolumab
por: Murakami, Yusuke, et al.
Publicado: (2022) -
Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis
por: Naito, Yujiro, et al.
Publicado: (2017) -
Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib
por: Kanaoka, Kensuke, et al.
Publicado: (2023) -
Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E‐positive non–small cell lung cancer: A case report
por: Taniguchi, Yoshihiko, et al.
Publicado: (2023)